Calls for drug which 'halves likelihood of high-risk women developing breast cancer' to be made freely available on NHS
Anastrozole found to be more effective than tamoxifen and raloxifene - the two preventative drugs made accessable to thousands on NHS this year
A breast cancer drug that protects women more effectively than either of the current treatments should be made freely available on the NHS, experts have urged.
In trials, the drug anastrozole was found to reduce the likelihood of breast cancer in post-menopausal women who were already at high risk by 53 per cent, making it more effective than tamoxifen and raloxifene - the two preventative drugs made available to thousands of women on the NHS earlier this year.
The study led by Queen Mary, University of London, and published in The Lancet, looked at almost 4,000 postmenopausal women, half of whom were given anastrozole daily for five years, while the other half took a placebo.
85 women in the placebo group developed breast cancer, compared to just 40 in the anastrozole group.
Tamoxifen and raloxifene reduce risk by around 40 per cent.
Professor Jack Cuzick, lead researcher and head of Queen Mary’s Centre for Cancer Prevention, said that anastrozole should now be the “drug of choice” for postmenopausal women with a family history of breast cancer, or other risk factors.
“This class of drugs is more effective than previous drugs and crucially, it has fewer side effects…in this study, the reported side effects were only slightly higher than in the placebo arm,” he said.
“Our priority now is ensuring that as many women as possible can benefit from these new findings,” Professor Cuzick added. “We strongly urge the National Institute for Health and Care Excellence (Nice) to consider adding anastrozole to their recommended drugs for women who are predisposed to developing breast cancer. By including this drug in their clinical guidelines, more women will benefit from this important advancement in preventive medicine.”
Professor Mark Baker, director of the Centre for Clinical Practice at Nice, said: "We will certainly consider this research - along with all other available evidence - when the Nice guideline on familial breast cancer is next updated.”
Life & Style blogs
DNA hope on schizophrenia: Research breakthrough points at over 100 genes
Husband creates spreadsheet detailing wife's 'excuses' for turning down sex
Apple has installed security backdoors on 600m iPhones and iPads, claims security researcher
UK pirates will get four warning letters a year
Xiaomi Mi4: 'Apple of China' launches flagship mobile to challenge the iPhone
- 1 Husband creates spreadsheet detailing wife's 'excuses' for turning down sex
- 2 Apple has installed security backdoors on 600m iPhones and iPads, claims security researcher
- 3 Saneie Masilela, 9, marries Helen Shabangu, 53 years his senior, for the second time
- 4 UK pirates will get four warning letters a year
- 5 Is Gideon Levy the most hated man in Israel or just the most heroic?
Competitive: The Green Recruitment Company: Job Title: Scheme Manager (BREEAM)...
Flexible, depending on experience: The Green Recruitment Company: Job Title: T...
£350 - £400 Per Day: Clearwater People Solutions Ltd: Project Manager job vaca...
£45000 - £50000 Per Annum + excellent benefits: Clearwater People Solutions Lt...